Meeram Noor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meeram Noor has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Rehman Azam
King Edward Medical University, Lahore, Pakistan
1 shared publication - Abubakar Nazir
Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan
1 shared publication - Ahmad Haroon
Department of Medicine, Sargodha Medical College, Faisal Masood Teaching Hospital, Sargodha, Punjab, Pakistan
1 shared publication Ahmad Hassan
Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan
1 shared publication- Alina Jamshed
Department of Medicine, CMH Multan Institute of Medical Sciences, Multan, Pakistan
1 shared publication - Arbab Khalid
Kirk Kerkorian School of Medicine at UNLV, Las Vegas, USA
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- 3 October 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessReal-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- Open Access
- 16 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e47261
Incremental benefits of catheter ablation in patients with structural heart disease undergoing implantable cardioverter-defibrillator therapy for ventricular arrhythmias: A PRISMA compliant systematic review and meta analysis
Background: Structural heart disease (SHD) significantly increases the risk of life-threatening ventricular arrhythmias (VAs), contributing to sudden cardiac death. Implantable cardioverter-defibrillators are the cornerstone of prevention but do not eliminate arrhythmia recurrences or reduce the arrhythmogenic substrate. Catheter ablation has emerged as a potential adjunctive therapy to reduce VA burden and implantable cardioverter-defibrillator (ICD) interventions in patients with SHD. This meta-analysis aimed to evaluate the incremental benefits of catheter ablation compared to antiarrhythmic drug (AAD) therapy or standard care in patients with SHD undergoing ICD implantation for VAs. Methods: A systematic search was conducted till April 2025 across PubMed/MEDLINE, Cochrane, google scholar and science direct following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies included patients with SHD receiving ICD therapy, comparing catheter ablation with any alternative treatment. Outcomes assessed included mortality, arrhythmia recurrence, disease burden, and ICD interventions. Statistical analysis was performed using Review Manager, calculating odds ratios (ORs) and 95% confidence intervals (CI), with heterogeneity assessed via I 2 statistics. Results: Eight studies were included, encompassing 536 patients in the catheter ablation group and 560 patients in the control group. Catheter ablation did not significantly reduce all-cause mortality (OR = 0.79, 95% CI: 0.48–1.29, P = .34), cardiovascular mortality (OR = 0.73, 95% CI: 0.37–1.43, P = .36), or death (OR = 0.86, 95% CI: 0.53–1.38, P = .52). However, catheter ablation was associated with a significant reduction in recurrent ventricular tachycardia (VT) (OR = 0.42, 95% CI: 0.27–0.64, P < .001) and cardiac hospitalization (OR = 0.55, 95% CI: 0.34–0.89, P = .015). No significant differences were observed for VT storm or electrical storm. Importantly, catheter ablation significantly reduced inappropriate ICD shocks (OR = 0.36, 95% CI: 0.20–0.66, P < .001), while rates of appropriate ICD shocks and antitachycardia pacing were similar between groups. Conclusion: Catheter ablation offers significant benefits in reducing arrhythmia burden and inappropriate ICD shocks but does not impact overall mortality compared to antiarrhythmic therapy in patients with SHD undergoing ICD implantation.
- 16 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e47261
Open AccessIncremental benefits of catheter ablation in patients with structural heart disease undergoing implantable cardioverter-defibrillator therapy for ventricular arrhythmias: A PRISMA compliant systematic review and meta analysis
Background: Structural heart disease (SHD) significantly increases the risk of life-threatening ventricular arrhythmias (VAs), contributing to sudden cardiac death. Implantable cardioverter-defibrillators are the cornerstone of prevention but do not eliminate arrhythmia recurrences or reduce the arrhythmogenic substrate. Catheter ablation has emerged as a potential adjunctive therapy to reduce VA burden and implantable cardioverter-defibrillator (ICD) interventions in patients with SHD. This meta-analysis aimed to evaluate the incremental benefits of catheter ablation compared to antiarrhythmic drug (AAD) therapy or standard care in patients with SHD undergoing ICD implantation for VAs. Methods: A systematic search was conducted till April 2025 across PubMed/MEDLINE, Cochrane, google scholar and science direct following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies included patients with SHD receiving ICD therapy, comparing catheter ablation with any alternative treatment. Outcomes assessed included mortality, arrhythmia recurrence, disease burden, and ICD interventions. Statistical analysis was performed using Review Manager, calculating odds ratios (ORs) and 95% confidence intervals (CI), with heterogeneity assessed via I 2 statistics. Results: Eight studies were included, encompassing 536 patients in the catheter ablation group and 560 patients in the control group. Catheter ablation did not significantly reduce all-cause mortality (OR = 0.79, 95% CI: 0.48–1.29, P = .34), cardiovascular mortality (OR = 0.73, 95% CI: 0.37–1.43, P = .36), or death (OR = 0.86, 95% CI: 0.53–1.38, P = .52). However, catheter ablation was associated with a significant reduction in recurrent ventricular tachycardia (VT) (OR = 0.42, 95% CI: 0.27–0.64, P < .001) and cardiac hospitalization (OR = 0.55, 95% CI: 0.34–0.89, P = .015). No significant differences were observed for VT storm or electrical storm. Importantly, catheter ablation significantly reduced inappropriate ICD shocks (OR = 0.36, 95% CI: 0.20–0.66, P < .001), while rates of appropriate ICD shocks and antitachycardia pacing were similar between groups. Conclusion: Catheter ablation offers significant benefits in reducing arrhythmia burden and inappropriate ICD shocks but does not impact overall mortality compared to antiarrhythmic therapy in patients with SHD undergoing ICD implantation.
- 28 April 2025
- Published by Springer Nature in Biological Trace Element Research
- Vol. 203 (12) , 6206-6212
Is There Any Role of Zinc and Copper in Severity and Progression of Osteoarthritis? A Review
Osteoarthritis (OA) is one of the most prevalent chronic diseases of the aging population, with an incidence of more than 250 million affected people and annual treatment costs exceeding $80 billion. Osteoarthritis involves pain, stiffness, reduced mobility, and swelling of the joints due to cartilage wear and tear and inflammation, which results in a broad system affecting the joints. This review focuses on the relationship between zinc and copper and the effects of these minerals on osteoarthritis. Osteoarthritis is a degenerative disease that currently affects millions of people and is characterized by the degradation of joint cartilage and inflammation. Zinc is crucial to the development of healthy cells, including cartilage, and copper keeps cartilage in balance and improves the immune response. If these elements are imbalanced, then symptoms of osteoarthritis may worsen, and studies have revealed that people with osteoarthritis exhibit increased levels of copper, which is the active factor in inflammation and cartilage breakdown. In osteoarthritis patients, the level of zinc is decreased, yet it plays an important role in bone and cartilage formation. Zinc and copper are interrelated because zinc has antioxidant properties, while copper might have a detrimental effect on cell injury. More investigations must be conducted on the therapeutic aspects of these processes and on how to improve the treatment of osteoarthritis. Knowledge of these relationships could allow for enhanced diagnosis, proper treatment, and therapy for people with osteoarthritis, hence enhancing quality of life.
- 28 April 2025
- Published by Springer Nature in Biological Trace Element Research
- Vol. 203 (12) , 6206-6212
Is There Any Role of Zinc and Copper in Severity and Progression of Osteoarthritis? A Review
Osteoarthritis (OA) is one of the most prevalent chronic diseases of the aging population, with an incidence of more than 250 million affected people and annual treatment costs exceeding $80 billion. Osteoarthritis involves pain, stiffness, reduced mobility, and swelling of the joints due to cartilage wear and tear and inflammation, which results in a broad system affecting the joints. This review focuses on the relationship between zinc and copper and the effects of these minerals on osteoarthritis. Osteoarthritis is a degenerative disease that currently affects millions of people and is characterized by the degradation of joint cartilage and inflammation. Zinc is crucial to the development of healthy cells, including cartilage, and copper keeps cartilage in balance and improves the immune response. If these elements are imbalanced, then symptoms of osteoarthritis may worsen, and studies have revealed that people with osteoarthritis exhibit increased levels of copper, which is the active factor in inflammation and cartilage breakdown. In osteoarthritis patients, the level of zinc is decreased, yet it plays an important role in bone and cartilage formation. Zinc and copper are interrelated because zinc has antioxidant properties, while copper might have a detrimental effect on cell injury. More investigations must be conducted on the therapeutic aspects of these processes and on how to improve the treatment of osteoarthritis. Knowledge of these relationships could allow for enhanced diagnosis, proper treatment, and therapy for people with osteoarthritis, hence enhancing quality of life.